aspirin has been researched along with Diarrhea in 68 studies
Aspirin: The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5)
acetylsalicylate : A benzoate that is the conjugate base of acetylsalicylic acid, arising from deprotonation of the carboxy group.
acetylsalicylic acid : A member of the class of benzoic acids that is salicylic acid in which the hydrogen that is attached to the phenolic hydroxy group has been replaced by an acetoxy group. A non-steroidal anti-inflammatory drug with cyclooxygenase inhibitor activity.
Diarrhea: An increased liquidity or decreased consistency of FECES, such as running stool. Fecal consistency is related to the ratio of water-holding capacity of insoluble solids to total water, rather than the amount of water present. Diarrhea is not hyperdefecation or increased fecal weight.
| Excerpt | Relevance | Reference |
|---|---|---|
| "A randomized double blind controlled clinical trial was conducted on 30 patients with cholera and 18 patients with severe non-cholera diarrhoea, to study the antisecretory effect of acetylsalicylic acid (aspirin)." | 9.06 | A randomized double blind trial of aspirin versus placebo in cholera and non-cholera diarrhoea. ( Bardhan, PK; Islam, A; Islam, MR; Rahman, M, 1986) |
| "Soluble aspirin given by mouth in divided dosage decreased intestinal fluid loss in infants and young children with acute gastroenteritis." | 9.05 | Aspirin in acute gastroenteritis: a clinical and microbiological study. ( Burke, V; Gracey, M; Phadke, MA; Raut, SK; Singh, B, 1984) |
| "The tolerance of ketoprofen (2-(3-benzoylphenyl)-propionic acid) was studied in sixteen patients with rheumatoid arthritis during a treatment period up to seven months." | 9.04 | Long-term treatment with ketoprofen in rheumatoid arthritis. A clinical trial with special reference to side-effects. ( Peltola, P, 1976) |
| " The purpose of the present study was to examine 2 potential mitigation strategies for flushing and gastrointestinal (GI) events associated with DMF treatment: aspirin (ASA) 325 mg pretreatment for flushing, and slow dose titration of DMF for flushing and GI events." | 7.81 | Effect of Aspirin Pretreatment or Slow Dose Titration on Flushing and Gastrointestinal Events in Healthy Volunteers Receiving Delayed-release Dimethyl Fumarate. ( Kurukulasuriya, NC; Li, J; O'Gorman, J; Phillips, G; Russell, HK; Viglietta, V, 2015) |
| "The misoprostol/aspirin-treated group had significantly (P < 0." | 6.67 | Use of synthetic prostaglandin E1 (misoprostol) for prevention of aspirin-induced gastroduodenal ulceration in arthritic dogs. ( Boudrieau, RJ; Labato, MA; Matz, ME; Murtaugh, RJ, 1993) |
| " Furthermore, the simpler dosing regimen, the absence of neutropenia, and the lower frequency of other side effects make it a safe alternative to ticlopidine." | 5.09 | Effectiveness of clopidogrel and aspirin versus ticlopidine and aspirin in preventing stent thrombosis after coronary stent implantation. ( Collins, M; Colombo, A; Iyer, S; Kreps, E; Maida, R; Moses, JW; Moussa, I; Oetgen, M; Roubin, G; Wang, X, 1999) |
| "Ninety-one normal, healthy volunteers participated in a single-center, double-blind, placebo-controlled, randomized, parallel group study: 1) to compare the prostaglandin E1 analog, misoprostol, given at a dose of 200 micrograms bid, with the recommended dose of 200 micrograms qid in protecting the gastroduodenal mucosa against injury due to anti-inflammatory doses of aspirin (3900 mg/day); and 2) to determine whether the reduced dose was associated with a lesser incidence of gastrointestinal (GI) side effects, particularly diarrhea." | 5.07 | A double-blind, placebo-controlled, 6-day evaluation of two doses of misoprostol in gastroduodenal mucosal protection against damage from aspirin and effect on bowel habits. ( Deysach, LG; Geis, GS; Kochman, RL; Lanza, FL; Rack, EM, 1991) |
| "A randomized double blind controlled clinical trial was conducted on 30 patients with cholera and 18 patients with severe non-cholera diarrhoea, to study the antisecretory effect of acetylsalicylic acid (aspirin)." | 5.06 | A randomized double blind trial of aspirin versus placebo in cholera and non-cholera diarrhoea. ( Bardhan, PK; Islam, A; Islam, MR; Rahman, M, 1986) |
| "Soluble aspirin given by mouth in divided dosage decreased intestinal fluid loss in infants and young children with acute gastroenteritis." | 5.05 | Aspirin in acute gastroenteritis: a clinical and microbiological study. ( Burke, V; Gracey, M; Phadke, MA; Raut, SK; Singh, B, 1984) |
| "The tolerance of ketoprofen (2-(3-benzoylphenyl)-propionic acid) was studied in sixteen patients with rheumatoid arthritis during a treatment period up to seven months." | 5.04 | Long-term treatment with ketoprofen in rheumatoid arthritis. A clinical trial with special reference to side-effects. ( Peltola, P, 1976) |
| " Two weeks after the regular dose was restarted (month 3), the patient had repeated bleeding (patient was receiving aspirin for previous MI) and had to stop ibrutinib again." | 4.93 | Walking a tightrope: clinical use of ibrutinib in mantle cell lymphoma in the elderly. ( Ruella, M; Soubeyran, P, 2016) |
| "In this cohort of patients with chronic diarrhea, we found use of aspirin and non-steroidal anti-inflammatory drugs, but not other implicated medications to be associated with the development of MC." | 4.12 | Nonsteroidal anti-inflammatory drug exposure and the risk of microscopic colitis. ( Amusin, DB; Gentile, NM; Goldberg, MJ; Goldstein, JL; Ture, A; Yen, EF; Yoo, J, 2022) |
| " The purpose of the present study was to examine 2 potential mitigation strategies for flushing and gastrointestinal (GI) events associated with DMF treatment: aspirin (ASA) 325 mg pretreatment for flushing, and slow dose titration of DMF for flushing and GI events." | 3.81 | Effect of Aspirin Pretreatment or Slow Dose Titration on Flushing and Gastrointestinal Events in Healthy Volunteers Receiving Delayed-release Dimethyl Fumarate. ( Kurukulasuriya, NC; Li, J; O'Gorman, J; Phillips, G; Russell, HK; Viglietta, V, 2015) |
| "The present study was undertaken to assess the activity/anti-inflammatory potential of Linum usitatissimum fixed oil against castor oil-induced diarrhoea, turpentine oil-induced joint oedema, formaldehyde and Complete Freund's Adjuvant (CFA)-induced arthritis in Wistar albino rats." | 3.76 | Therapeutic effect of Linum usitatissimum (flaxseed/linseed) fixed oil on acute and chronic arthritic models in albino rats. ( Kaithwas, G; Majumdar, DK, 2010) |
| " The anti-diarrheal effects were found in not only acidic NSAID, but also in basic NSAID and SAID which did not inhibited ultraviolet erythema, acute death induced by arachidonic acid injection and PGs biosynthesis." | 3.66 | Effect of anti-inflammatory drugs on endotoxin-induced diarrhea in mice. ( Fujimura, H; Tsurumi, K, 1983) |
| "The misoprostol/aspirin-treated group had significantly (P < 0." | 2.67 | Use of synthetic prostaglandin E1 (misoprostol) for prevention of aspirin-induced gastroduodenal ulceration in arthritic dogs. ( Boudrieau, RJ; Labato, MA; Matz, ME; Murtaugh, RJ, 1993) |
| "Ticlopidine has not been formally compared with aspirin in patients with a completed stroke." | 2.67 | Ticlopidine versus aspirin for the prevention of recurrent stroke. Analysis of patients with minor stroke from the Ticlopidine Aspirin Stroke Study. ( Harbison, JW, 1992) |
| "The diarrhea was improved in 8 patients, although in 2 it relapsed 48 hours after improvement was 1st observed." | 1.25 | Aspirin in radiation-induced diarrhoea. ( Dalley, V; Mennie, AT, 1973) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 42 (61.76) | 18.7374 |
| 1990's | 9 (13.24) | 18.2507 |
| 2000's | 5 (7.35) | 29.6817 |
| 2010's | 6 (8.82) | 24.3611 |
| 2020's | 6 (8.82) | 2.80 |
| Authors | Studies |
|---|---|
| Fahrenholtz, KE | 1 |
| Silverzweig, MZ | 1 |
| Germane, N | 1 |
| Crowley, HJ | 1 |
| Simko, BA | 1 |
| Dalton, C | 1 |
| Yen, EF | 1 |
| Amusin, DB | 1 |
| Yoo, J | 1 |
| Ture, A | 1 |
| Gentile, NM | 1 |
| Goldberg, MJ | 1 |
| Goldstein, JL | 1 |
| Zhang, SW | 1 |
| Xu, RH | 1 |
| Chen, D | 1 |
| Orieke, D | 1 |
| Ohaeri, OC | 1 |
| Ijeh, II | 1 |
| Ijioma, SN | 1 |
| Lee, WS | 1 |
| Margolskee, E | 1 |
| Kofman, AD | 1 |
| Sizemore, EK | 1 |
| Detelich, JF | 1 |
| Albrecht, B | 1 |
| Piantadosi, AL | 1 |
| Cattalini, M | 1 |
| Della Paolera, S | 1 |
| Zunica, F | 1 |
| Bracaglia, C | 1 |
| Giangreco, M | 1 |
| Verdoni, L | 1 |
| Meini, A | 1 |
| Sottile, R | 1 |
| Caorsi, R | 1 |
| Zuccotti, G | 1 |
| Fabi, M | 1 |
| Montin, D | 1 |
| Meneghel, A | 1 |
| Consolaro, A | 1 |
| Dellepiane, RM | 1 |
| Maggio, MC | 1 |
| La Torre, F | 1 |
| Marchesi, A | 1 |
| Simonini, G | 1 |
| Villani, A | 1 |
| Cimaz, R | 1 |
| Ravelli, A | 1 |
| Taddio, A | 1 |
| Hammami, MB | 1 |
| Gill, R | 1 |
| Thiruvengadam, N | 1 |
| Oh, DY | 1 |
| Beck, K | 1 |
| Mahadevan, U | 1 |
| Kattah, MG | 1 |
| Kupsky, DF | 1 |
| Tweet, MS | 1 |
| Anavekar, NS | 1 |
| O'Gorman, J | 1 |
| Russell, HK | 1 |
| Li, J | 1 |
| Phillips, G | 1 |
| Kurukulasuriya, NC | 1 |
| Viglietta, V | 1 |
| Ruella, M | 1 |
| Soubeyran, P | 1 |
| Kaithwas, G | 1 |
| Majumdar, DK | 1 |
| Darshan, J | 1 |
| Shaw, E | 1 |
| Green, B | 1 |
| Gallagher, PJ | 1 |
| Gadola, SD | 1 |
| BARNESS, LA | 2 |
| YOUNG, LN | 2 |
| Blassneck, K | 1 |
| Nusko, G | 1 |
| Niedobitek, G | 1 |
| Hahn, EG | 1 |
| Harsch, IA | 1 |
| Jones, L | 1 |
| Griffin, S | 1 |
| Palmer, S | 1 |
| Main, C | 1 |
| Orton, V | 1 |
| Sculpher, M | 1 |
| Sudlow, C | 1 |
| Henderson, R | 1 |
| Hawkins, N | 1 |
| Riemsma, R | 1 |
| Qvigstad, G | 1 |
| Hatlen-Rebhan, P | 1 |
| Brenna, E | 1 |
| Waldum, HL | 1 |
| Tuteja, AK | 1 |
| Talley, NJ | 1 |
| Joos, SK | 1 |
| Tolman, KG | 1 |
| Hickam, DH | 1 |
| Buisseret, P | 1 |
| Burke, V | 2 |
| Gracey, M | 2 |
| Korman, SH | 1 |
| Berant, M | 1 |
| Alon, U | 1 |
| Wise, CM | 1 |
| Knight, AP | 1 |
| Lucas, MJ | 1 |
| Morris, CJ | 1 |
| Ellis, RP | 1 |
| Phillips, RW | 1 |
| Phadke, MA | 1 |
| Raut, SK | 1 |
| Singh, B | 1 |
| Tsurumi, K | 1 |
| Fujimura, H | 1 |
| Goyan, JE | 1 |
| Gullikson, GW | 1 |
| Sender, M | 1 |
| Bass, P | 1 |
| Rasková, H | 2 |
| Skegg, DC | 1 |
| Doll, R | 1 |
| Lieb, J | 1 |
| Perkins, WE | 1 |
| Bianchi, RG | 1 |
| Tremont, SJ | 1 |
| Collins, PW | 1 |
| Casler, JJ | 1 |
| Fenton, RL | 1 |
| Wagner, GM | 1 |
| McGrath, MP | 1 |
| Stolzenbach, JC | 1 |
| Kowalski, DL | 1 |
| Murtaugh, RJ | 1 |
| Matz, ME | 1 |
| Labato, MA | 1 |
| Boudrieau, RJ | 1 |
| Oshima, T | 1 |
| Moussa, I | 1 |
| Oetgen, M | 1 |
| Roubin, G | 1 |
| Colombo, A | 1 |
| Wang, X | 1 |
| Iyer, S | 1 |
| Maida, R | 1 |
| Collins, M | 1 |
| Kreps, E | 1 |
| Moses, JW | 1 |
| Yagi, K | 1 |
| Nakamura, A | 1 |
| Sekine, A | 1 |
| Watanabe, H | 1 |
| Mennie, AT | 2 |
| Dalley, VM | 1 |
| Dinneen, LC | 1 |
| Collier, HO | 1 |
| Pounder, RE | 1 |
| Sechserová, M | 1 |
| Sechser, T | 1 |
| Elis, J | 1 |
| Vanĕcek, J | 1 |
| Polák, L | 1 |
| Matĕjovská, D | 1 |
| Raska, K | 1 |
| Novak, E | 1 |
| Lee, JG | 1 |
| Seckman, CE | 1 |
| Phillips, JP | 1 |
| DiSanto, AR | 1 |
| Peltola, P | 1 |
| Dodge, JA | 2 |
| Hamdi, I | 2 |
| Walker, S | 1 |
| Ciccolunghi, SN | 1 |
| Levi, B | 1 |
| Chaudri, HA | 1 |
| Brenner, WE | 1 |
| Dingfelder, R | 1 |
| Staurovsky, LG | 1 |
| Hitotsubashi, S | 1 |
| Fujii, Y | 1 |
| Yamanaka, H | 1 |
| Okamoto, K | 1 |
| Harbison, JW | 1 |
| Castor, B | 1 |
| Thorén, A | 1 |
| Barkenius, G | 1 |
| Lanza, FL | 1 |
| Kochman, RL | 1 |
| Geis, GS | 1 |
| Rack, EM | 1 |
| Deysach, LG | 1 |
| Xu, ZR | 1 |
| Kornegay, ET | 1 |
| Sweet, LA | 1 |
| Lindemann, MD | 1 |
| Veit, HP | 1 |
| Watkins, BA | 1 |
| Yamashiro, Y | 1 |
| Shimizu, T | 1 |
| Oguchi, S | 1 |
| Sato, M | 1 |
| Ghosh, HK | 1 |
| Islam, A | 1 |
| Bardhan, PK | 1 |
| Islam, MR | 1 |
| Rahman, M | 1 |
| Jager, LP | 1 |
| Zijlstra, FJ | 1 |
| Hoogendoorn, A | 1 |
| Nabuurs, MJ | 1 |
| Mohan, M | 1 |
| Daral, TS | 1 |
| Singh, HP | 1 |
| Sachdev, HP | 1 |
| Bhargava, SK | 1 |
| Dalley, V | 1 |
| Smythies, JR | 1 |
| Russell, RO | 1 |
| Nakano, J | 2 |
| Newmark, SR | 1 |
| Himathongkam, T | 1 |
| Shane, JM | 1 |
| Kriegel, H | 1 |
| Schramm, E | 1 |
| Finck, AD | 1 |
| Katz, RL | 1 |
| Koss, MC | 1 |
| Marshall, AJ | 1 |
| Sheridan, P | 1 |
| Holmes, EL | 1 |
| Hill, AG | 1 |
| Cardoe, N | 1 |
| Coldwell, BB | 1 |
| Boyd, EM | 1 |
| Simpson, MR | 1 |
| Simpson, NR | 1 |
| Masheter, HC | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized, Double-Blind, Phase 3b Study to Evaluate Effects of Aspirin or Dose Titration on Flushing and Gastrointestinal Events Following Oral Administration of BG00012 Dosed at 240 mg BID[NCT01568112] | Phase 3 | 173 participants (Actual) | Interventional | 2012-04-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
For participants with more than 1 flushing episode during a visit interval, the average duration for the visit interval was used. The average duration is calculated as: the total duration of all flushing episodes / the total number of flushing episodes. (NCT01568112)
Timeframe: Day 1 to Week 8
| Intervention | minutes (Mean) |
|---|---|
| Placebo | 98.4 |
| BG00012 | 63.2 |
| BG00012 + ASA | 69.8 |
| BG00012 Slow Titration | 68.9 |
For participants with more than 1 flushing episode during a visit interval, the average duration for the visit interval was used. The average duration is calculated as: the total duration of all flushing episodes / the total number of flushing episodes. (NCT01568112)
Timeframe: Week 1 to Week 4
| Intervention | minutes (Mean) |
|---|---|
| Placebo | 117.6 |
| BG00012 | 67.6 |
| BG00012 + ASA | 89.8 |
| BG00012 Slow Titration | 69.2 |
For participants with more than 1 flushing episode during a visit interval, the average duration for the visit interval was used. The average duration is calculated as: the total duration of all flushing episodes / the total number of flushing episodes. (NCT01568112)
Timeframe: Week 5 to Week 8
| Intervention | minutes (Mean) |
|---|---|
| Placebo | 113.2 |
| BG00012 | 55.7 |
| BG00012 + ASA | 73.2 |
| BG00012 Slow Titration | 56.0 |
The MAGISS is a participant-reported questionnaire about side effects of the gastrointestinal system following drug administration, and is based on a 0- to 10-point scale, with 0 representing absence of symptoms and 10 representing the most severe symptoms. A participant was considered having overall GI side effect if he/she had a score of >=1 for at least one of the GI side effects including nausea, diarrhea, upper abdominal pain, lower abdominal pain, vomiting, indigestion, constipation, bloating and flatulence. (NCT01568112)
Timeframe: Day 1 to Week 8
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo | 73 |
| BG00012 | 81 |
| BG00012 + ASA | 81 |
| BG00012 Slow Titration | 86 |
The MOGISS is a questionnaire about overall side effects related to the gastrointestinal system (including nausea, diarrhea, upper abdominal pain, lower abdominal pain, vomiting, indigestion, constipation, bloating, and flatulence) during the 24 hours prior to each AM dose. Participants were to answer the questions at the same time each day, before the morning drug administration. (NCT01568112)
Timeframe: Day 1 to Week 8
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo | 59 |
| BG00012 | 70 |
| BG00012 + ASA | 79 |
| BG00012 Slow Titration | 79 |
The MOGISS is a questionnaire about overall side effects related to the gastrointestinal system (including nausea, diarrhea, upper abdominal pain, lower abdominal pain, vomiting, indigestion, constipation, bloating, and flatulence) during the 24 hours prior to each AM dose. Participants were to answer the questions at the same time each day, before the morning drug administration. (NCT01568112)
Timeframe: Week 1 to Week 4
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo | 57 |
| BG00012 | 65 |
| BG00012 + ASA | 67 |
| BG00012 Slow Titration | 71 |
The MAGISS is a participant-reported questionnaire about side effects of the gastrointestinal system following drug administration, and is based on a 0- to 10-point scale, with 0 representing absence of symptoms and 10 representing the most severe symptoms. A participant was considered having overall GI side effect if he/she had a score of >=1 for at least one of the GI side effects including nausea, diarrhea, upper abdominal pain, lower abdominal pain, vomiting, indigestion, constipation, bloating and flatulence. (NCT01568112)
Timeframe: Day 1 to Week 4
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo | 66 |
| BG00012 | 81 |
| BG00012 + ASA | 79 |
| BG00012 Slow Titration | 79 |
The MOGISS is a questionnaire about overall side effects related to the gastrointestinal system (including nausea, diarrhea, upper abdominal pain, lower abdominal pain, vomiting, indigestion, constipation, bloating, and flatulence) during the 24 hours prior to each AM dose. Participants were to answer the questions at the same time each day, before the morning drug administration. (NCT01568112)
Timeframe: Week 5 to Week 8
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo | 34 |
| BG00012 | 59 |
| BG00012 + ASA | 50 |
| BG00012 Slow Titration | 58 |
The MAGISS is a participant-reported questionnaire about side effects of the gastrointestinal system following drug administration, and is based on a 0- to 10-point scale, with 0 representing absence of symptoms and 10 representing the most severe symptoms. A participant was considered having overall GI side effect if he/she had a score of >=1 for at least one of the GI side effects including nausea, diarrhea, upper abdominal pain, lower abdominal pain, vomiting, indigestion, constipation, bloating and flatulence. (NCT01568112)
Timeframe: Week 5 to Week 8
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo | 41 |
| BG00012 | 59 |
| BG00012 + ASA | 53 |
| BG00012 Slow Titration | 61 |
Participant-reported flushing events during the overall treatment period, recorded on the hand-held participant reporting device (eDiary) as assessed by MGFSS. The MGFSS measures the side effects related to flushing during the past 24 hours. Flushing means redness, warmth, tingling or itching of the skin. Each question is rated on a scale from 0 (no flushing side effects) to 10 (extreme flushing side effects). Day 1 data are not included in the analysis because MGFSS question refers to events reported in the 24 hours after the first dose on Day 1. (NCT01568112)
Timeframe: Day 2 to Week 8
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo | 43 |
| BG00012 | 86 |
| BG00012 + ASA | 74 |
| BG00012 Slow Titration | 93 |
Participant-reported flushing events during Weeks 1 to 4 of treatment (combined), recorded on the hand-held participant reporting device (eDiary) as assessed by MGFSS. The MGFSS measures the side effects related to flushing during the past 24 hours. Flushing means redness, warmth, tingling or itching of the skin. Each question is rated on a scale from 0 (no flushing side effects) to 10 (extreme flushing side effects). Day 1 data are not included in the analysis because MGFSS question refers to events reported in the 24 hours after the first dose on Day 1. (NCT01568112)
Timeframe: Day 2 to Week 4
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo | 41 |
| BG00012 | 84 |
| BG00012 + ASA | 62 |
| BG00012 Slow Titration | 90 |
Participant-reported flushing events during Weeks 5 to 8 of treatment (combined), recorded on the hand-held participant reporting device (eDiary) as assessed by MGFSS. The MGFSS measures the side effects related to flushing during the past 24 hours. Flushing means redness, warmth, tingling or itching of the skin. Each question is rated on a scale from 0 (no flushing side effects) to 10 (extreme flushing side effects). Day 1 data are not included in the analysis because MGFSS question refers to last 24 hours flushing score. (NCT01568112)
Timeframe: Week 5 to Week 8
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo | 24 |
| BG00012 | 86 |
| BG00012 + ASA | 67 |
| BG00012 Slow Titration | 85 |
Number of participants with clinical laboratory shifts from baseline in blood chemistry values. Shift to low includes normal to low, high to low, and unknown to low. Shift to high includes normal to high, low to high, and unknown to high. ALP=alkaline phosphatase, ALT=alanine aminotransferase, AST=aspartate aminotransferase, GGT=gamma-glutamyl transferase, LDH=lactate dehydrogenase, BUN=blood urea nitrogen. (NCT01568112)
Timeframe: Day 1 to Week 8
| Intervention | participants (Number) | |||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ALP: shift to high; n=44, 42, 43, 42 | ALT: shift to high; n=44, 42, 43, 42 | AST: shift to high; n=44, 43, 43, 41 | GGT: shift to high; n=44, 41, 43, 42 | LDH: shift to low; n=44, 43, 43, 42 | LDH: shift to high; n=44, 43, 43, 42 | Total bilirubin: shift to high; n=44, 42, 42, 40 | BUN: shift to low; n=44, 43, 43, 42 | BUN: shift to high; n=44, 43, 41, 42 | Creatinine: shift to low; n=44, 43, 43, 42 | Creatinine: shift to high; n=44, 43, 43, 42 | Uric Acid: shift to low; n=44, 43, 43, 42 | Uric Acid: shift to high; n=44, 43, 43, 42 | Sodium: shift to low; n=44, 43, 43, 42 | Sodium: shift to high; n=44, 43, 43, 42 | Potassium: shift to low: n=44, 43, 43, 42 | Potassium: shift to high: n=44, 42, 42, 41 | Chloride: shift to low; n=44, 43, 43, 42 | Chloride: shift to high; n=44, 43, 43, 42 | Bicarbonate: shift to low; n=44, 43, 43, 42 | Bicarbonate: shift to high; n=44, 43, 43, 42 | Calcium: shift to low; n=44, 42, 43, 42 | Calcium: shift to high; n=44, 43, 43, 42 | Glucose: shift to low; n=43, 43, 41, 41 | Glucose: shift to high; n=44, 43, 43, 42 | Magnesium: shift to low; n=44, 43, 43, 42 | Magnesium: shift to high; n=44, 43, 43, 42 | Phosphorus: shift to low; n=44, 43, 43, 41 | Phosphorus: shift to high; n=44, 43, 43, 42 | Albumin: shift to low; n=44, 43, 43, 42 | Albumin: shift to high; n=44, 43, 43, 42 | Direct bilirubin: shift to high; n=44, 43, 43, 40 | Total protein: shift to low; n=44, 41, 43, 41 | Total protein: shift to high; n=44, 43, 43, 42 | |
| BG00012 | 0 | 2 | 3 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| BG00012 + ASA | 0 | 5 | 4 | 2 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 1 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| BG00012 Slow Titration | 0 | 2 | 1 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Placebo | 0 | 1 | 2 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 1 | 0 | 1 | 0 | 0 | 0 | 3 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Number of participants with clinical laboratory shifts from baseline in hematology values. Shift to low includes normal to low, high to low, and unknown to low. Shift to high includes normal to high, low to high, and unknown to high. abs=absolute (NCT01568112)
Timeframe: Day 1 to Week 8
| Intervention | participants (Number) | ||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| White blood cells: shift to low; n=43, 43, 43, 41 | White blood cells: shift to high; n=44, 43, 43, 42 | Neutrophils abs: shift to low; n=42, 42, 42, 41 | Neutrophils abs: shift to high; n=44, 43, 43, 42 | Lymphocytes abs: shift to low; n=43, 43, 43, 41 | Lymphocytes abs: shift to high; n=44, 43, 42, 42 | Monocytes abs: shift to low; n=44, 43, 43, 42 | Monocytes abs: shift to high; n=44, 43, 43, 42 | Eosinophils abs: shift to low; n=44, 43, 43, 42 | Eosinophils abs: shift to high; n=44, 43, 43, 42 | Basophils abs: shift to high; n=44, 43, 43, 42 | Red blood cells: shift to low; n=44, 43, 43, 40 | Red blood cells: shift to high; n=44, 43, 43, 42 | Hemoglobin: shift to low; n=43, 41, 43, 42 | Hemoglobin: shift to high; n=44, 43, 43, 42 | Hematocrit: shift to low; n=44, 43, 43, 42 | Hematocrit: shift to high; n=43, 43, 43, 42 | Platelets: shift to low; n=44, 43, 43, 42 | Platelets: shift to high; n=44, 41, 43, 42 | |
| BG00012 | 2 | 0 | 6 | 0 | 5 | 0 | 0 | 0 | 0 | 5 | 1 | 2 | 0 | 3 | 0 | 2 | 0 | 0 | 0 |
| BG00012 + ASA | 0 | 1 | 2 | 0 | 2 | 0 | 0 | 0 | 0 | 6 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 |
| BG00012 Slow Titration | 0 | 0 | 2 | 1 | 3 | 0 | 0 | 0 | 0 | 6 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 |
| Placebo | 0 | 0 | 3 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
Number of participants with clinical laboratory shifts from baseline in urinalysis values.Shift to low includes normal to low, high to low, and unknown to low. Shift to high includes normal to high, low to high, and unknown to high. Shift to positive includes negative to positive and unknown to positive. RBC=red blood cells, WBC=white blood cells. (NCT01568112)
Timeframe: Day 1 to Week 8
| Intervention | participants (Number) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Specific gravity: shift to low; n=44, 43, 43, 42 | Specific gravity: shift to high; n=44, 42, 43, 42 | pH: shift to low; n=44, 43, 43, 42 | pH: shift to high; n=44, 43, 43, 42 | Blood: shift to positive; n=42, 39, 39, 42 | Color: shift to positive; n=41, 43, 41, 39 | Glucose: shift to positive; n=44, 43, 43, 41 | Ketones: shift to positive; n=44, 43, 43, 42 | Protein: shift to positive; n=44, 41, 43, 41 | Microscopic RBC; n=44, 40, 40, 41 | Microscopic WBC; n=43, 40, 41, 42 | |
| BG00012 | 0 | 0 | 0 | 0 | 6 | 1 | 2 | 7 | 1 | 4 | 9 |
| BG00012 + ASA | 0 | 2 | 0 | 0 | 1 | 4 | 1 | 9 | 1 | 1 | 3 |
| BG00012 Slow Titration | 0 | 0 | 0 | 0 | 2 | 5 | 0 | 6 | 1 | 2 | 3 |
| Placebo | 0 | 0 | 0 | 0 | 3 | 2 | 0 | 1 | 0 | 3 | 4 |
Duration is calculated as follows: [(GI side effect) end date/time - (GI side effect) start date/time]/3600. For GI side effects with no end date, the end date is imputed using the last diary date/time. For subjects with more than 1 GI episode during a visit interval, the average duration for the study visit interval is used. The average duration is calculated as the total duration of the GI side effect / the total number of GI side effects. (NCT01568112)
Timeframe: Day 1 to Week 8
| Intervention | hours (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Nausea; n=12, 21, 21, 22 | Diarrhea; n=20, 20 17, 15 | Upper abdominal pain; n=17, 14, 19, 19 | Lower abdominal pain; n=12, 19, 17, 16 | Vomiting; n=3, 3, 3, 2 | Indigestion; n=12, 13, 12, 12 | Constipation; n=6, 8, 13, 11 | Bloating; n=14, 14, 21, 12 | Flatulence; n=23, 20, 22, 20 | |
| BG00012 | 7.05 | 2.92 | 6.67 | 13.93 | 10.08 | 16.49 | 28.20 | 16.91 | 9.06 |
| BG00012 + ASA | 10.01 | 14.66 | 15.88 | 10.84 | 1.88 | 3.80 | 14.26 | 9.68 | 68.93 |
| BG00012 Slow Titration | 2.98 | 4.97 | 3.83 | 7.75 | 0.75 | 4.91 | 20.90 | 77.24 | 63.84 |
| Placebo | 9.74 | 5.57 | 19.08 | 6.65 | 5.87 | 4.76 | 20.49 | 9.50 | 16.41 |
Duration is calculated as follows: [(GI side effect) end date/time - (GI side effect) start date/time]/3600. For GI side effects with no end date, the end date is imputed using the last diary date/time. For subjects with more than 1 GI episode during a visit interval, the average duration for the study visit interval is used. The average duration is calculated as the total duration of the GI side effect / the total number of GI side effects. (NCT01568112)
Timeframe: Week 1 to Week 4
| Intervention | hours (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Nausea; n=10, 18, 18, 20 | Diarrhea; n=13, 20, 14, 14 | Upper abdominal pain; n=14, 14, 17, 15 | Lower abdominal pain; n=9, 18, 14, 13 | Vomiting; n=2, 2, 2, 2 | Indigestion; n=11, 11, 9, 11 | Constipation; n=4, 8, 11, 11 | Bloating; n=9, 14, 19, 11 | Flatulence; n=21, 17, 22, 19 | |
| BG00012 | 7.23 | 2.53 | 6.81 | 14.20 | 5.63 | 29.00 | 27.61 | 13.81 | 9.34 |
| BG00012 + ASA | 11.18 | 16.04 | 17.65 | 12.51 | 2.53 | 3.93 | 15.12 | 11.07 | 35.86 |
| BG00012 Slow Titration | 2.86 | 4.97 | 4.31 | 6.30 | 0.75 | 5.05 | 21.28 | 95.69 | 61.13 |
| Placebo | 10.47 | 5.20 | 21.37 | 5.40 | 4.31 | 5.08 | 17.05 | 6.70 | 12.83 |
Duration is calculated as follows: [(GI side effect) end date/time - (GI side effect) start date/time]/3600. For GI side effects with no end date, the end date is imputed using the last diary date/time. For subjects with more than 1 GI episode during a visit interval, the average duration for the study visit interval is used. The average duration is calculated as the total duration of the GI side effect / the total number of GI side effects. (NCT01568112)
Timeframe: Week 5 to Week 8
| Intervention | hours (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Nausea; n=4, 9, 6, 9 | Diarrhea; n=12, 13, 6, 8 | Upper abdominal pain; n=6, 5, 5, 5 | Lower abdominal pain; n=7, 5, 5, 9 | Vomiting; n=1, 1, 1, 0 | Indigestion; n=6, 7, 7, 5 | Constipation; n=5, 2, 4, 4 | Bloating; n=7, 8, 7, 8 | Flatulence; n=9, 13, 7, 10 | |
| BG00012 | 4.34 | 6.62 | 1.12 | 3.98 | 19.00 | 2.57 | 15.47 | 18.52 | 7.21 |
| BG00012 + ASA | 2.66 | 7.05 | 1.86 | 2.84 | 0.58 | 5.02 | 21.30 | 4.16 | 105.86 |
| BG00012 Slow Titration | 2.34 | 2.14 | 1.73 | 22.54 | NA | 1.63 | 18.24 | 85.64 | 18.48 |
| Placebo | 3.96 | 4.50 | 5.29 | 6.63 | 9.00 | 2.43 | 23.35 | 12.49 | 44.67 |
↑=increase; ↓=decrease; BL=baseline; bpm=beats per minute; SBP=systolic blood pressure; DBP=diastolic blood pressure; b/m=breaths per minute (NCT01568112)
Timeframe: Day 1 to Week 8
| Intervention | participants (Number) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Temperature >38°C + ↑ from BL of ≥1°C | Pulse >120 bpm or ↑ from BL of >20 bpm | Pulse <50 bpm or ↓ from BL of >20 bpm | SBP >180 mm Hg or ↑ from BL of >40 mm Hg | SBP <90 mm Hg or ↓ from BL of >30 mm Hg | DBP >105 mm Hg or ↑ from BL of >30 mm Hg | DBP <50 mm Hg or ↓ from BL of >20 mm Hg | Respiration rate >25 b/m or ↑ from BL of ≥50% | Respiration rate 10 b/m or ↓ from BL of ≥50% | |
| BG00012 | 0 | 10 | 4 | 0 | 2 | 0 | 3 | 2 | 0 |
| BG00012 + ASA | 0 | 20 | 3 | 0 | 1 | 0 | 0 | 3 | 0 |
| BG00012 Slow Titration | 0 | 17 | 4 | 0 | 1 | 0 | 1 | 3 | 0 |
| Placebo | 0 | 8 | 11 | 1 | 1 | 0 | 1 | 1 | 0 |
Shift to 'abnormal, not adverse event' includes unknown or normal to 'abnormal, not adverse event.' Shift to 'abnormal, adverse event' includes unknown or normal to 'abnormal, adverse event.' (NCT01568112)
Timeframe: Day 1 to Week 8
| Intervention | participants (Number) | |
|---|---|---|
| Shift to abnormal, not adverse event | Shift to abnormal, adverse event | |
| BG00012 | 3 | 0 |
| BG00012 + ASA | 2 | 0 |
| BG00012 Slow Titration | 4 | 0 |
| Placebo | 2 | 0 |
AE: any untoward medical occurrence that does not necessarily have a causal relationship with treatment. SAE: any untoward medical occurrence that at any dose: results in death; in the view of the Investigator, places the subject at immediate risk of death; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; results in a congenital anomaly/birth defect; any other medically important event that, in the opinion of the Investigator, may jeopardize the subject or may require intervention to prevent one of the other outcomes. An AE was considered treatment-emergent if it occurred after the start of study treatment or was present prior to the start of study treatment but subsequently worsened. (NCT01568112)
Timeframe: Day 1 up to end of Safety Follow-up (9 weeks)
| Intervention | participants (Number) | ||||||
|---|---|---|---|---|---|---|---|
| Any event | Moderate or severe event | Severe event | Related event | Serious event | Discontinuation of treatment due to an event | Withdrawal from study due to an event | |
| BG00012 | 24 | 13 | 4 | 17 | 1 | 4 | 4 |
| BG00012 + ASA | 26 | 12 | 4 | 16 | 0 | 6 | 6 |
| BG00012 Slow Titration | 26 | 11 | 1 | 18 | 0 | 3 | 3 |
| Placebo | 24 | 10 | 0 | 8 | 0 | 2 | 2 |
Participant-reported flushing side effect events during the treatment period recorded on the eDiary as assessed by MFSS. MFSS questionnaire measures the side effects related to flushing following drug administration. Flushing means redness, warmth, tingling or itching of the skin. This questionnaire relates only to the period of time since the investigational drug was administered and was to be completed within 10 hours of taking the study drug (2 times/day). Each question is rated on a scale from 0 (no flushing side effects) to 10 (extreme flushing side effects). (NCT01568112)
Timeframe: Day 1 to Week 8
| Intervention | percentage of participants (Number) | ||||
|---|---|---|---|---|---|
| Overall flushing events | Overall redness events | Overall warmth events | Overall tingling events | Overall itching events | |
| BG00012 | 91 | 86 | 93 | 88 | 86 |
| BG00012 + ASA | 81 | 77 | 84 | 67 | 72 |
| BG00012 Slow Titration | 98 | 90 | 98 | 86 | 98 |
| Placebo | 41 | 27 | 41 | 23 | 20 |
Participant-reported flushing side effect events during Weeks 1 to 4 recorded on the eDiary as assessed by MFSS. MFSS questionnaire measures the side effects related to flushing following drug administration. Flushing means redness, warmth, tingling or itching of the skin. This questionnaire relates only to the period of time since the investigational drug was administered and was to be completed within 10 hours of taking the study drug (2 times/day). Each question is rated on a scale from 0 (no flushing side effects) to 10 (extreme flushing side effects). (NCT01568112)
Timeframe: Week 1 to Week 4
| Intervention | percentage of participants (Number) | ||||
|---|---|---|---|---|---|
| Overall flushing events | Overall redness events | Overall warmth events | Overall tingling events | Overall itching events | |
| BG00012 | 86 | 81 | 88 | 84 | 77 |
| BG00012 + ASA | 72 | 63 | 67 | 51 | 56 |
| BG00012 Slow Titration | 98 | 88 | 95 | 83 | 95 |
| Placebo | 41 | 25 | 41 | 23 | 16 |
Participant-reported flushing side effect events during Weeks 1 to 4 recorded on the eDiary as assessed by MFSS. MFSS questionnaire measures the side effects related to flushing following drug administration. Flushing means redness, warmth, tingling or itching of the skin. This questionnaire relates only to the period of time since the investigational drug was administered and was to be completed within 10 hours of taking the study drug (2 times/day). Each question is rated on a scale from 0 (no flushing side effects) to 10 (extreme flushing side effects). (NCT01568112)
Timeframe: Week 5 to Week 8
| Intervention | percentage of participants (Number) | ||||
|---|---|---|---|---|---|
| Overall flushing events | Overall redness events | Overall warmth events | Overall tingling events | Overall itching events | |
| BG00012 | 86 | 78 | 86 | 81 | 78 |
| BG00012 + ASA | 72 | 64 | 75 | 64 | 58 |
| BG00012 Slow Titration | 85 | 79 | 82 | 70 | 61 |
| Placebo | 24 | 15 | 17 | 15 | 22 |
Severity of GI-related events using the MAGISS to measure GI symptoms (nausea, diarrhea, upper abdominal pain, lower abdominal pain, vomiting, indigestion, constipation, bloating, flatulence), based on a 0- to 10-point scale, with 0 representing absence of symptoms and 10 representing the most severe symptoms. (NCT01568112)
Timeframe: Day 1 to Week 4
| Intervention | units on a scale (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Nausea | Diarrhea | Upper abdominal pain | Lower abdominal pain | Vomiting | Indigestion | Constipation | Bloating | Flatulence | |
| BG00012 | 1.6 | 1.8 | 1.1 | 1.4 | 0.3 | 0.9 | 0.9 | 1.1 | 1.3 |
| BG00012 + ASA | 1.6 | 1.5 | 1.7 | 1.3 | 0.3 | 0.6 | 0.6 | 1.3 | 1.4 |
| BG00012 Slow Titration | 1.5 | 1.0 | 1.4 | 1.2 | 0.2 | 0.9 | 0.9 | 1.0 | 1.6 |
| Placebo | 0.7 | 1.0 | 0.8 | 0.5 | 0.2 | 0.7 | 0.4 | 0.5 | 1.3 |
Severity of GI-related events using the MAGISS to measure GI symptoms (nausea, diarrhea, upper abdominal pain, lower abdominal pain, vomiting, indigestion, constipation, bloating, flatulence), based on a 0- to 10-point scale, with 0 representing absence of symptoms and 10 representing the most severe symptoms. (NCT01568112)
Timeframe: Week 5 to Week 8
| Intervention | units on a scale (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Nausea | Diarrhea | Upper abdominal pain | Lower abdominal pain | Vomiting | Indigestion | Constipation | Bloating | Flatulence | |
| BG00012 | 0.9 | 1.4 | 0.5 | 0.4 | 0.1 | 0.5 | 0.1 | 0.7 | 1.2 |
| BG00012 + ASA | 0.8 | 0.8 | 0.4 | 0.5 | 0.1 | 0.5 | 0.6 | 0.7 | 0.4 |
| BG00012 Slow Titration | 0.9 | 0.7 | 0.6 | 0.9 | 0.0 | 0.4 | 0.3 | 0.8 | 0.9 |
| Placebo | 0.4 | 1.0 | 0.6 | 0.6 | 0.2 | 0.4 | 0.4 | 0.5 | 0.8 |
Worst severity of participant-reported flushing events during Weeks 1-4 of treatment combined, recorded on the eDiary as assessed by MFSS. MFSS questionnaire measures the side effects related to flushing following drug administration. Flushing means redness, warmth, tingling or itching of the skin. This questionnaire relates only to the period of time since the investigational drug was administered and was to be completed within 10 hours of taking the study drug (2 times/day). Each question is rated on a scale from 0 (no flushing side effects) to 10 (extreme flushing side effects). (NCT01568112)
Timeframe: Day 1 to Week 4
| Intervention | units on a scale (Mean) | ||||
|---|---|---|---|---|---|
| Overall flushing | Redness | Warmth | Tingling | Itching | |
| BG00012 | 4.4 | 3.8 | 4.0 | 3.4 | 3.2 |
| BG00012 + ASA | 2.4 | 1.6 | 2.3 | 1.6 | 1.3 |
| BG00012 Slow Titration | 5.6 | 5.1 | 5.2 | 4.0 | 4.3 |
| Placebo | 1.2 | 0.7 | 1.2 | 0.5 | 0.5 |
Worst severity of participant-reported flushing events during Weeks 1-4 of treatment combined, recorded on the eDiary as assessed by MFSS. MFSS questionnaire measures the side effects related to flushing following drug administration. Flushing means redness, warmth, tingling or itching of the skin.This questionnaire relates only to the period of time since the investigational drug was administered and was to be completed within 10 hours of taking the study drug (2 times/day). Each question is rated on a scale from 0 (no flushing side effects) to 10 (extreme flushing side effects). (NCT01568112)
Timeframe: Week 5 to Week 8
| Intervention | units on a scale (Mean) | ||||
|---|---|---|---|---|---|
| Overall flushing | Redness | Warmth | Tingling | Itching | |
| BG00012 | 3.8 | 3.6 | 3.9 | 3.3 | 3.1 |
| BG00012 + ASA | 3.3 | 2.9 | 3.1 | 2.3 | 2.3 |
| BG00012 Slow Titration | 3.1 | 2.9 | 2.9 | 2.2 | 1.8 |
| Placebo | 0.9 | 0.4 | 0.8 | 0.3 | 0.7 |
8 reviews available for aspirin and Diarrhea
| Article | Year |
|---|---|
Drug Exposure and Risk of Microscopic Colitis: A Systematic Review and Meta-Analysis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Colitis; Colitis, Microscopic; Diarrhea; Humans | 2023 |
Walking a tightrope: clinical use of ibrutinib in mantle cell lymphoma in the elderly.
Topics: Adenine; Aged; Aspirin; Diarrhea; Hemorrhage; Humans; Lymphoma, Mantle-Cell; Male; Neoplasm Staging; | 2016 |
Clinical effectiveness and cost-effectiveness of clopidogrel and modified-release dipyridamole in the secondary prevention of occlusive vascular events: a systematic review and economic evaluation.
Topics: Aspirin; Clopidogrel; Cost-Benefit Analysis; Delayed-Action Preparations; Diarrhea; Dipyridamole; Dr | 2004 |
Drug treatment of allergic gastroenteritis.
Topics: Adult; Allergens; Antibody-Producing Cells; Antidiarrheals; Antigen-Antibody Reactions; Aspirin; Dia | 1980 |
Review: prostaglandins in diarrheal states.
Topics: Aspirin; Bacterial Infections; Child; Cholera Toxin; Colonic Diseases; Cyclic AMP; Diarrhea; Dinopro | 1981 |
The prostaglandins: their significance in clinical practice.
Topics: Abortion, Induced; Anemia, Hemolytic; Animals; Aspirin; Asthma; Chemical Phenomena; Chemistry; Cycli | 1974 |
Pathophysiologic roles of prostaglandins and the action of aspirin-like drugs.
Topics: Analgesics; Animals; Aspirin; Cardiovascular System; Cats; Central Nervous System; Diarrhea; Digesti | 1973 |
Review of flufenamic acid in rheumatoid arthritis.
Topics: Anti-Inflammatory Agents; Arthritis, Rheumatoid; Aspirin; Clinical Trials as Topic; Diarrhea; Dyspep | 1966 |
15 trials available for aspirin and Diarrhea
| Article | Year |
|---|---|
Aspirin in acute gastroenteritis: a clinical and microbiological study.
Topics: Acute Disease; Aeromonas; Aspirin; Bacterial Infections; Child, Preschool; Clinical Trials as Topic; | 1984 |
Use of synthetic prostaglandin E1 (misoprostol) for prevention of aspirin-induced gastroduodenal ulceration in arthritic dogs.
Topics: Animals; Aspirin; Diarrhea; Dog Diseases; Dogs; Double-Blind Method; Duodenoscopy; Female; Gastroint | 1993 |
Effectiveness of clopidogrel and aspirin versus ticlopidine and aspirin in preventing stent thrombosis after coronary stent implantation.
Topics: Aged; Aspirin; Clopidogrel; Coronary Angiography; Coronary Disease; Coronary Thrombosis; Diarrhea; D | 1999 |
Treatment of radiation-induced gastrointestinal distress with acetylsalicylate.
Topics: Antacids; Aspirin; Buffers; Clinical Trials as Topic; Diarrhea; Drug Combinations; Drug Evaluation; | 1975 |
Unfavorable effect of atropine-diphenoxylate (Lomotil) therapy in lincomycin-caused diarrhea.
Topics: Administration, Oral; Adult; Aspirin; Caffeine; Clinical Trials as Topic; Diarrhea; Diphenoxylate; H | 1976 |
Long-term treatment with ketoprofen in rheumatoid arthritis. A clinical trial with special reference to side-effects.
Topics: Analgesics; Arthritis, Rheumatoid; Aspirin; Benzophenones; Clinical Trials as Topic; Diarrhea; Drug | 1976 |
[Clinical experiences with Voltaren a new nonsteroid antirheumatic agent].
Topics: Aniline Compounds; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Aspirin; Clinical Trials as Topi | 1975 |
Ticlopidine versus aspirin for the prevention of recurrent stroke. Analysis of patients with minor stroke from the Ticlopidine Aspirin Stroke Study.
Topics: Adult; Aspirin; Cerebrovascular Disorders; Diarrhea; Double-Blind Method; Female; Humans; Male; Midd | 1992 |
Failure of aspirin in symptomatic treatment of acute diarrhoea.
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Aspirin; Diarrhea; Double-Blind Method; F | 1991 |
A double-blind, placebo-controlled, 6-day evaluation of two doses of misoprostol in gastroduodenal mucosal protection against damage from aspirin and effect on bowel habits.
Topics: Adult; Aspirin; Diarrhea; Double-Blind Method; Duodenal Diseases; Duodenoscopy; Female; Gastric Muco | 1991 |
A randomized double blind trial of aspirin versus placebo in cholera and non-cholera diarrhoea.
Topics: Adult; Aspirin; Cholera; Clinical Trials as Topic; Diarrhea; Double-Blind Method; Feces; Female; Hum | 1986 |
Aspirin in childhood gastroenteritis.
Topics: Aspirin; Child, Preschool; Clinical Trials as Topic; Diarrhea; Gastroenteritis; Humans; Infant; Male | 1985 |
Experimental observations on flufenamic, mefenamic, and meclofenamic acids. IV. Toleration by normal human subjects.
Topics: Adult; Anti-Inflammatory Agents; Aspirin; Biphenyl Compounds; Blood Coagulation; Blood Urea Nitrogen | 1966 |
Review of flufenamic acid in rheumatoid arthritis.
Topics: Anti-Inflammatory Agents; Arthritis, Rheumatoid; Aspirin; Clinical Trials as Topic; Diarrhea; Dyspep | 1966 |
A clinical trial of flufenamic acid in the treatment of rheumatoid arthritis.
Topics: Abdomen, Acute; Acetaminophen; Aluminum; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Aspartate | 1966 |
46 other studies available for aspirin and Diarrhea
| Article | Year |
|---|---|
3-Phenyl-5-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]indole-2-carbonitrile, a potent inhibitor of prostaglandin synthetase and of platelet aggregation.
Topics: Animals; Arachidonic Acids; Aspirin; Cyclooxygenase Inhibitors; Diarrhea; Humans; In Vitro Technique | 1979 |
Nonsteroidal anti-inflammatory drug exposure and the risk of microscopic colitis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Colitis, Microscopic; Colonoscopy; Diarrhea; Femal | 2022 |
Gastrointestinal and uterine smooth muscles relaxant and anti-inflammatory effects of corchorus olitorius leaf extract in laboratory animal models.
Topics: Abortion, Spontaneous; Animals; Anti-Inflammatory Agents; Antidiarrheals; Aspirin; Corchorus; Diarrh | 2020 |
Leukoerythroblastosis and plasmacytoid lymphocytes in a child with SARS-CoV-2-associated multisystem inflammatory syndrome.
Topics: Anti-Inflammatory Agents; Aspirin; Betacoronavirus; Child; Clinical Laboratory Techniques; Coronavir | 2020 |
A young adult with COVID-19 and multisystem inflammatory syndrome in children (MIS-C)-like illness: a case report.
Topics: Adult; Aspirin; Betacoronavirus; Coronavirus Infections; Cough; COVID-19; COVID-19 Drug Treatment; D | 2020 |
Defining Kawasaki disease and pediatric inflammatory multisystem syndrome-temporally associated to SARS-CoV-2 infection during SARS-CoV-2 epidemic in Italy: results from a national, multicenter survey.
Topics: Age Distribution; Antirheumatic Agents; Aspirin; C-Reactive Protein; Child; Child, Preschool; Corona | 2021 |
Balancing the Checkpoint: Managing Colitis Associated with Dual Checkpoint Inhibitors and High-Dose Aspirin.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; As | 2019 |
30-year-old man with chest pain and nausea.
Topics: Acute Coronary Syndrome; Adult; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Aspirin; Ba | 2014 |
Effect of Aspirin Pretreatment or Slow Dose Titration on Flushing and Gastrointestinal Events in Healthy Volunteers Receiving Delayed-release Dimethyl Fumarate.
Topics: Abdominal Pain; Adult; Aspirin; Constipation; Delayed-Action Preparations; Diarrhea; Dimethyl Fumara | 2015 |
Therapeutic effect of Linum usitatissimum (flaxseed/linseed) fixed oil on acute and chronic arthritic models in albino rats.
Topics: Acute Disease; Alanine Transaminase; Albinism; Animals; Arthritis, Experimental; Aspartate Aminotran | 2010 |
Intestinal ischaemia and mesenteric necrosis in a heavy smoker.
Topics: Abdominal Pain; Aspirin; Diarrhea; Humans; Jejunal Diseases; Male; Mesenteric Arteries; Middle Aged; | 2013 |
A SIMPLIFIED VIEW OF FLUID THERAPY.
Topics: Acidosis; Adrenal Insufficiency; Aspirin; Calcium; Child; Cystic Fibrosis; Dehydration; Diabetes Mel | 1964 |
A SIMPLIFIED VIEW OF FLUID THERAPY.
Topics: Acidosis; Adrenal Insufficiency; Anuria; Aspirin; Body Weight; Burns; Calcium; Child; Cystic Fibrosi | 1964 |
[Chronic diarrhea caused by NSAIDs].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Chronic Disease; Colitis; Collagen; Colonoscopy; D | 2004 |
Capsule endoscopy in clinical routine in patients with suspected disease of the small intestine: a 2-year prospective study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cycloo | 2006 |
Abdominal bloating in employed adults: prevalence, risk factors, and association with other bowel disorders.
Topics: Adult; Aged; Aspirin; Colonic Diseases, Functional; Comorbidity; Constipation; Cross-Sectional Studi | 2008 |
Studies with enterotoxigenic microorganisms: effects of candidate antidiarrhoeals in experimental animals in vivo.
Topics: Aluminum Hydroxide; Animals; Antidiarrheals; Aspirin; Bacterial Infections; Charcoal; Chlorpromazine | 1984 |
Effect of salicylates on intestinal secretion in calves given (intestinal loops) Escherichia coli heat-stable enterotoxin.
Topics: Animals; Aspirin; Cattle; Cattle Diseases; Diarrhea; Enterotoxins; Escherichia coli; Intestinal Secr | 1983 |
Effect of anti-inflammatory drugs on endotoxin-induced diarrhea in mice.
Topics: Animals; Anti-Inflammatory Agents; Arachidonic Acid; Arachidonic Acids; Aspirin; Diarrhea; Drug Inte | 1983 |
Ticlopidine: quo vadis? Adverse reactions in man.
Topics: Anticoagulants; Aspirin; Diarrhea; Humans; Neutropenia; Product Surveillance, Postmarketing; Thiophe | 1984 |
Laxative-like effects of nonsteroidal anti-inflammatory drugs on intestinal fluid movement and membrane integrity.
Topics: Alprostadil; Animals; Anti-Inflammatory Agents; Aspirin; Body Fluids; Cathartics; Cricetinae; Diarrh | 1982 |
[Transfer of data to man and pathological models].
Topics: Animals; Aspirin; Cattle; Diarrhea; Disease Models, Animal; Humans; Kinetics; Sulfamethazine; Trimet | 1982 |
Record linkage for drug monitoring.
Topics: Aged; Aspirin; Cerebral Hemorrhage; Computers; Delivery, Obstetric; Diarrhea; Digoxin; Drug-Related | 1981 |
Prostaglandin synthesis inhibitors in prophylaxis of coffee intolerance.
Topics: Adult; Aspirin; Coffee; Diarrhea; Female; Humans; Prostaglandins | 1980 |
Polymer delivery of the active isomer of misoprostol: a solution to the intestinal side effect problem.
Topics: Animals; Antacids; Aspirin; Biological Availability; Butadienes; Depression, Chemical; Diarrhea; Dog | 1994 |
[Predictive factors for development of hemolytic uremic syndrome (HUS) and early intensive treatments for prevention of HUS enterohemorrhagic Escherichia coli infection].
Topics: Abdominal Pain; Adolescent; Age Factors; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroi | 1997 |
Nonsteroidal anti-inflammatory drug-associated colitis with a histology of collagenous colitis.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Colitis; Collagen; Colonoscopy; Diarrhea; Fe | 2001 |
Letter: Danger of aspirin during pelvic irradiation.
Topics: Aspirin; Diarrhea; Female; Humans; Radiotherapy; Uterine Neoplasms | 1975 |
Letter: Danger of aspirin during pelvic irradiation.
Topics: Aspirin; Diarrhea; Humans; Pelvic Neoplasms; Prostaglandin Antagonists; Radiation Injuries | 1975 |
Ontogenic drug studies in calves. II. Changes in salicylate levels and metabolism in calves with diarrhoea.
Topics: Animals; Animals, Newborn; Aspirin; Cattle; Cattle Diseases; Cholera Toxin; Diarrhea; Escherichia co | 1979 |
Prostaglandin-induced diarrhoea.
Topics: Aspirin; Child, Preschool; Diarrhea; Female; Humans; Indomethacin; Prostaglandins | 1977 |
The efficacy and safety of intramuscularly administered 15(S) 15 methyl prostaglandin E2 methyl ester for induction of artificial abortion.
Topics: Abortion, Induced; Adolescent; Adult; Aspirin; Atropine; Diarrhea; Diphenoxylate; Drug Administratio | 1975 |
Some properties of purified Escherichia coli heat-stable enterotoxin II.
Topics: Animals; Aspirin; Bacterial Toxins; Biological Assay; Cholera Toxin; Diarrhea; Dinoprostone; Enterot | 1992 |
Effects of feeding aspirin and soybean oil to weanling pigs.
Topics: Animal Feed; Animals; Aspirin; Blood Coagulation; Diarrhea; Fatty Acids; Female; Immunity; Least-Squ | 1990 |
Prostaglandins in the plasma and stool of children with rotavirus gastroenteritis.
Topics: Aspirin; Child; Child, Preschool; Diarrhea; Diarrhea, Infantile; Dinoprost; Dinoprostone; Feces; Fem | 1989 |
Using aspirin to treat diarrhoea.
Topics: Aspirin; Child; Diarrhea; Humans; Reye Syndrome | 1987 |
Enteropooling in piglets induced by soya-peptone mediated via an increased biosynthesis of prostanoids.
Topics: Animal Feed; Animals; Aspirin; Diarrhea; Eicosanoic Acids; Fatty Acids; Glycine max; Guinea Pigs; Je | 1986 |
Toddler diarrhoea: observations on the effects of aspirin and loperamide.
Topics: Antidiarrheals; Aspirin; Child, Preschool; Cyclooxygenase Inhibitors; Diarrhea; Diarrhea, Infantile; | 1985 |
Aspirin in radiation-induced diarrhoea.
Topics: Aged; Aspirin; Diarrhea; Female; Humans; Middle Aged; Radiotherapy; Uterine Neoplasms | 1973 |
Letter: Possible role of prostaglandins in idiopathic postural hypotension.
Topics: Adult; Aspirin; Diarrhea; Female; Humans; Hypotension, Orthostatic; Intestines; Prostaglandin Antago | 1974 |
Hyperthyroid crisis.
Topics: Adrenal Cortex Hormones; Aspirin; Atrial Fibrillation; Diarrhea; Fever; Guanethidine; Humans; Iodide | 1974 |
[Induction of gastrointestinal hemorrhages in the rat by acetylsalicylic acid and acetylsalicylic acid-containing drugs].
Topics: Administration, Oral; Animals; Aspirin; Chromium Radioisotopes; Diarrhea; Drug Combinations; Erythro | 1974 |
Prevention of cholera-induced intestinal secretion in the cat by aspirin.
Topics: Animals; Aspirin; Cats; Cholera; Diarrhea; Disease Models, Animal; Female; Intestinal Secretions; Ma | 1972 |
Side effects of benorylate.
Topics: Acetaminophen; Aged; Arthritis, Rheumatoid; Aspirin; Diarrhea; Esters; Female; Humans | 1973 |
The acute rectal toxicity of acetylsalicylic acid.
Topics: Adrenal Glands; Animals; Aspirin; Ataxia; Body Weight; Brain; Coma; Diarrhea; Diuresis; Dyspnea; Fee | 1966 |
New drugs. 8. Flufenamic acid in rheumatoid arthritis. Comparison with aspirin and the results of extended treatment.
Topics: Anti-Inflammatory Agents; Arthritis, Rheumatoid; Aspirin; Blood Sedimentation; Diarrhea; Flufenamic | 1966 |